Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
| Website: | www.corbuspharma.com |
| Email: | ir@corbuspharma.com |
| Main Phone: | +1 617 963-0100 |
| Address: | 500 River Ridge Drive |
| Address 2: | Second Floor |
| State: | MA |
| City / Town: | Norwood |
| Country: | USA |
| Postal Code: | 02062 |
| Exchange: | NSD |
| CEO: | Yuval Cohen |
| Employees: | 77 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
Pot stocks are hot. There’s a lot of risk in the group – many of the companies will not survive – but the winners will post monster gains over the next few years.
A few names to know.
Trade Ideas’ SaaS model powered by A.I. has outperformed our benchmark and other indices since its inception.
AngioSoma, Inc. (SONA) is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease ('PAD')
Sick of big Wall Street banks but looking for the steady dividend from investing in banks? Try investing in regional banks.
Getting a shot at growth doesn't necessarily mean spending a fortune. There's plenty of stocks out there for less than a buck a share that still have some real potential.
Louisville-based Globelimmune (GBIM), a developer of cancer drugs, has voluntary decided to delist and deregister its common stock from the Nasdaq.
MicroCaps work this way...the stock gets a meteoric ride doubling in value and the bankers show up and sell shares below current prices to raise operating capital. It happens every day
GlobeImmune (GBIM) rallied another 30% today on 10 million shares at mid point of today's trading trading $2.65 today after opening the week at $1.19 more than a 100% higher.
Undoubtedly, the most interesting aspect of Globelmmune's collaborations with Gilead (GILD) and Celgene (CELG) and for a company valued at $12m as of mid-June 2016...
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
| Website: | www.corbuspharma.com |
| Email: | ir@corbuspharma.com |
| Main Phone: | +1 617 963-0100 |
| Address: | 500 River Ridge Drive |
| Address 2: | Second Floor |
| State: | MA |
| City / Town: | Norwood |
| Country: | USA |
| Postal Code: | 02062 |
| Exchange: | NSD |
| CEO: | Yuval Cohen |
| Employees: | 77 |
| NAICS: | Biological Product (except Diagnostic) Manufacturing(325414) |
Pot stocks are hot. There’s a lot of risk in the group – many of the companies will not survive – but the winners will post monster gains over the next few years.
A few names to know.
Trade Ideas’ SaaS model powered by A.I. has outperformed our benchmark and other indices since its inception.
AngioSoma, Inc. (SONA) is a clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease ('PAD')
Sick of big Wall Street banks but looking for the steady dividend from investing in banks? Try investing in regional banks.
Getting a shot at growth doesn't necessarily mean spending a fortune. There's plenty of stocks out there for less than a buck a share that still have some real potential.
Louisville-based Globelimmune (GBIM), a developer of cancer drugs, has voluntary decided to delist and deregister its common stock from the Nasdaq.
MicroCaps work this way...the stock gets a meteoric ride doubling in value and the bankers show up and sell shares below current prices to raise operating capital. It happens every day
GlobeImmune (GBIM) rallied another 30% today on 10 million shares at mid point of today's trading trading $2.65 today after opening the week at $1.19 more than a 100% higher.
Undoubtedly, the most interesting aspect of Globelmmune's collaborations with Gilead (GILD) and Celgene (CELG) and for a company valued at $12m as of mid-June 2016...
| Last Price 4.84 | Change $ -0.005 | Change % -0.10 | Tick N/A |
| Bid 4.83 | Bid Size 200.00 | Ask 4.84 | Ask Size 200.00 |
| Open 4.85 | High 4.90 | Low 4.82 | Prev Close 4.84 |
| Last Trade | Volume 31,924 | 52 Wk Hi 9.11 | 52 Wk Low 4.44 |
| Market Cap 312.6 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 64,651,593.00 | EPS (TTM) -0.97 | PE Ratio N/A | Exchange NSD |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 32 | 32 | 32 | 32 |
| Low Target Price Estimate | 20 | 20 | 20 | 20 |
| Mean Target Price Estimate | 24.67 | 24.67 | 24.67 | 24.67 |
| Standard Deviation | 6.43 | 6.43 | 6.43 | 6.43 |
| Date of Most Recent Estimate | 05/22/18 | 05/22/18 | 05/22/18 | 05/22/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 8-K | Report of unscheduled material events or corporate changes. | 12 | 2018-06-13 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-06 |
| 3 | Initial statement of beneficial ownership of securities | 2 | 2018-06-06 |
| 8-K | Report of unscheduled material events or corporate changes. | 8 | 2018-06-06 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-29 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-29 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-29 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-29 |
| 8-K | Report of unscheduled material events or corporate changes. | 4 | 2018-05-24 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-16 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 |
| Moderate Buy | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.2 | 1.17 | 1.17 | 1.17 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait